Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kidney; Complications, Allograft Clear all
Completed Phase 1 Interventional

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

NCT00063817
View directory record Official record
Conditions
End-stage Renal Disease, Renal Transplantation, Kidney Transplantation
Interventions
Conditioning Regimen
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Jun 26, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

NCT00817206
View directory record Official record
Conditions
Renal Failure
Interventions
LCP-Tacro, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Jun 26, 2026, 5:20 AM EDT
Terminated Phase 1 Interventional

Contrast-Enhanced Ultrasound for Kidney Transplant

NCT02911714
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Lumason Contrast-Enhanced Ultrasound
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jun 26, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional

Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion

NCT00497926
View directory record Official record
Conditions
Kidney Failure
Interventions
Enriched Hematopoietic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Jun 26, 2026, 5:20 AM EDT
Completed No phase listed Observational

Angiotensin-Converting Enzyme Gene Polymorphism and the Risk of Chronic Allograft Nephropathy

NCT00006328
View directory record Official record
Conditions
Kidney Disease
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 26, 2026, 5:20 AM EDT
Terminated Phase 3 Interventional

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

NCT00005113
View directory record Official record
Conditions
End-Stage Renal Disease, Kidney Transplantation
Interventions
Cyclosporine, Sirolimus, Tacrolimus
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 20 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Jun 26, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Tocilizumab for Renal Graft Inflammation

NCT02108600
View directory record Official record
Conditions
Late Complication From Kidney Transplant
Interventions
Tocilizumab
Drug
Lead sponsor
Flavio Vincenti
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Jun 26, 2026, 5:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Berinert (C1INH) vs Placebo for DGF/IRI

NCT04696146
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Berinert, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jun 26, 2026, 5:20 AM EDT
Recruiting Not applicable Interventional

Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study

NCT06337942
View directory record Official record
Conditions
Bladder Disease, Bladder, Neurogenic, Bladder Cancer, Kidney Failure
Interventions
Bladder Transplantation, Combined Kidney and Bladder Transplantation
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jun 26, 2026, 5:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of B Cells in Kidney Allograft Dysfunction

NCT02294032
View directory record Official record
Conditions
Kidney; Complications, Allograft, Transplantation Infection
Interventions
Immunosuppressive Agents
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
2 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Jun 26, 2026, 5:20 AM EDT
Completed Not applicable Interventional

Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy

NCT03323021
View directory record Official record
Conditions
Partial Nephrectomy, Kidney Cancer, Renal Function Aggravated
Interventions
Dehydrated human amnion/chorion membrane, Standard of Care
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jun 26, 2026, 5:20 AM EDT
Completed Not applicable Interventional

Nonmyeloablative Allogeneic Transplant

NCT01272817
View directory record Official record
Conditions
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Waldenstrom Macroglobulinemia, Breast Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Ovarian Cancer, Thymoma
Interventions
Nonmyeloablative Allogeneic Transplant
Procedure
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 72 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Jun 26, 2026, 5:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Jun 26, 2026, 5:20 AM EDT
Completed Phase 3 Interventional

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

NCT00000935
View directory record Official record
Conditions
End-Stage Renal Disease, Kidney Transplantation
Interventions
Intravenous immune globulin (IVIG)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jun 26, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Angiotensin II Blockade for Chronic Allograft Nephropathy

NCT00067990
View directory record Official record
Conditions
Kidney Disease, Proteinuria
Interventions
Losartan 100mg, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Jun 26, 2026, 5:20 AM EDT
Not listed Phase 1 Interventional

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

NCT05195125
View directory record Official record
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Jun 26, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.

NCT00446459
View directory record Official record
Conditions
Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
Interventions
mycophenolate mofetil (CellCept)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Jun 26, 2026, 5:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Renal Allograft Tolerance Through Mixed Chimerism

NCT01780454
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
MEDI-507, Rituximab, Total Body Irradiation, Thymic Irradiation
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Jun 26, 2026, 5:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

NCT05027906
View directory record Official record
Conditions
Prevention of Rejection in Kidney Transplant
Interventions
AT-1501
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jun 26, 2026, 5:20 AM EDT
Not listed Phase 1Phase 2 Interventional

Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion

NCT00498160
View directory record Official record
Conditions
Renal Failure
Interventions
Enriched Hematopoietic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Jun 26, 2026, 5:20 AM EDT
Active, not recruiting Phase 1 Interventional

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

NCT04540380
View directory record Official record
Conditions
Renal Failure
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Jun 26, 2026, 5:20 AM EDT
Completed Phase 1 Interventional

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

NCT00807794
View directory record Official record
Conditions
Kidney Diseases
Interventions
MEDI-507
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
4
States / cities
New Haven, Connecticut • Bloomington, Indiana • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2008 · Synced Jun 26, 2026, 5:20 AM EDT
Not yet recruiting No phase listed Observational

Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function

NCT07645599
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent, DEFINITY®
Diagnostic Test · Drug
Lead sponsor
Roderick Tan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 26, 2026, 5:20 AM EDT
Completed No phase listed Observational

Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France

NCT03723668
View directory record Official record
Conditions
Kidney Failure, Transplant;Failure,Kidney
Interventions
Not listed
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
Not listed
Enrollment
94,017 participants
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jun 26, 2026, 5:20 AM EDT